This is a working overview of angiotensin IV, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-08. Anything still debated is marked as such rather than presented as settled.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Water contamination is primarily caused by the discharge of untreated wastewater from industrial and commercial activities. The effluent from various enterprises, which contains varying levels of contaminants, is dumped into rivers or other water resources. The wastewater may have a high proportion of organic and inorganic contaminants at the initial discharge. Industries generate wastewater as a result of fabrication processes, processes dealing with paper and pulp, textiles, chemicals, and from various streams such as cooling towers, boilers, and production lines. Treatment for drinking water production involves the removal of contaminants and/or inactivation of any potentially harmful microbes from raw water to produce water that is pure enough for human consumption without any short term or long term risk of any adverse health effect. In general terms, the greatest microbial risks are associated with ingestion of water that is contaminated with human or animal (including bird) feces. Feces can be a source of pathogenic bacteria, viruses, protozoa and helminths. The removal or destruction of microbial pathogens is essential, and commonly involves the use of reactive chemical agents such as suspended solids, to remove bacteria, algae, viruses, fungi, and minerals including iron and manganese. Research including Professor Linda Lawton's group at Robert Gordon University, Aberdeen is working to improve detection of cyanobacteria. These substances continue to cause great harm to several less developed countries who do not have access to effective water purification systems.
=== Second and third nucleotide recognition === The second and third position nucleotides are recognized by YxxCxxxF and GTS sites. This process is very important because this gives eRF1 the ability to discriminate the stop codon from a uracil starting sense codons that codes for an amino acid. For example the cysteine amino acid is coded by the codon UGU. The first step in discriminating stop from sense codons is to distinguish purines from pyrimidines, since all stop codons have purine nucleotides in the +2 and +3 position. Two highly conserved amino acid residues Glu55 and Tyr125 (located in the YxxCxxxF motif) work in tandem to hydrogen bond with the N6 nitrogen atom on the adenosine/guanine nucleotide. This interaction excludes the possibility of pyrimidines in the +2 and +3 position. Further discrimination of the purines in the +2 and +3 position is need since UGG is a sense codon for tryptophan. In the case of UGG, the Glu55 residue is repelled from the strong negative charge from the two guanine nucleotides. Since no extensive hydrogen bonding occurred, the codon is not recognized as a stop codon. A very important residue in eRF1 is the Cys127 in the YxxCxxxF motif, which forms 2 hydrogen bonds with a Watson and Crick's edge located on the mRNA. The hydrogen bonding allows further stability of the eRF1-stop codon complex in multiple orientations and allows stacking/hydrogen bonding of the +2 and +3 position of the stop codon. The strength and number of the stacks on the second and third position allows eRF1 to discriminate stop codons from sense codons.
To do this, known controls are tested consecutively with unknown samples. By comparing the readouts of the controls with their known profiles the instrument can be confirmed to have been working properly at the time the unknowns were tested. Standards are also used to determine the instrument's limit of detection and limit of quantification for various common substances. Calculated quantities must be above the limit of detection to be confirmed as present and above the limit of quantification to be quantified. If the value is below the limit the value is not considered reliable.
Sources: en.wikipedia.org
Xing Qiyi (Chinese: 邢其毅; pinyin: Xíng Qíyì; Wade–Giles: Hsing Ch'i-i) was a Chinese organic chemist who contributed to the total synthesis of bovine insulin, Xing is still well-known nowadays in China as the main editor of a highly-influential organic chemistry textbook. He was a member of China Democratic League since 1952.
Bats are subject to predation from birds of prey, such as owls, hawks, and falcons. J. Rydell and J. R. Speakman argue that bats evolved nocturnality during the early Eocene period to avoid predators. Other zoologists find the evidence to be unclear and contradictory. Twenty-two (maybe twenty-three or twenty-four) species of tropical New World snakes are known to eat bats; they may wait for them at the entrances of their refuges or attack them inside. As are most mammals, bats are hosts to a number of internal and external parasites. Among ectoparasites, bats carry fleas and mites, as well as specific parasites such as bat bugs and bat flies (Nycteribiidae and Streblidae). Bats generally do not host lice, possibly due to high competition from other parasites, including the more specialised ones. Internal parasites of bats include tapeworms, roundworms and flukes.
Ibogaine's hallucinogenic effects not being mediated by serotonin 5-HT2A receptor activation has been said to be in accordance with its hallucinogenic effects in humans being qualitatively distinct from and unlike those of serotonergic psychedelics but instead similar to those of harmala alkaloids. It is also in accordance with the fact that unlike serotonergic psychedelics like LSD, neither ibogaine nor harmala alkaloids cause pupil dilation or increase blood pressure in humans. Conversely, unlike serotonergic psychedelics, ibogaine and harmaline are said to cause balance disturbances and vomiting to a greater extent than any other psychoactive drug besides alcohol. Ibogaine shows appreciable affinity for the NMDA receptor. However, the NMDA receptor antagonists phencyclidine (PCP) and dizocilpine (MK-801) fail to substitute for ibogaine and ibogaine fails to substitute for these NMDA receptor antagonists in rodents and/or monkeys. Hence, NMDA receptor antagonism does not appear to be involved in the subjective effects of ibogaine. Neither μ-opioid receptor agonists nor κ-opioid receptor agonists like U-50,488 substitute for ibogaine. In addition, the opioid antagonist naloxone did not substitute for ibogaine. However, naltrexone partially substitutes for ibogaine. In addition, the mixed opioid agonists and antagonists pentazocine, diprenorphine, and nalorphine partially substituted for ibogaine and this could be antagonized by naloxone. The preceding findings suggest a role of opioid receptors but not the NMDA receptor in the effects of ibogaine.
Sources: en.wikipedia.org
The fiber angle (the angle the fiber makes with the long axis of the body) plays a critical role in torsion, if the angle is greater than 54°44', during muscle contraction, torsion and elongation will occur. If the fiber angle is less than 54°44', torsion and shortening will occur.
=== Pharmacokinetics === A 2007 human pharmacokinetic study of sodium RLA demonstrated the maximum concentration in plasma and bioavailability are significantly greater than the free acid form, and rivals plasma levels achieved by intravenous administration of the free acid form. Additionally, high plasma levels comparable to those in animal models where Nrf2 was activated were achieved. The various forms of LA are not bioequivalent. Very few studies compare individual enantiomers with racemic lipoic acid. It is unclear if twice as much racemic lipoic acid can replace RLA. The toxic dose of LA in cats is much lower than that in humans or dogs and produces hepatocellular toxicity.
La Union was a secret society that became dedicated to the Annexationist Movement, thinking that it would be better for Cuba to become a fully integrated state of the United States, rather than to remain a Spanish possession.
===== Junior residency (Part I) ===== Duration: 24 to 36 months. Objective: Develop core clinical competencies and foundational knowledge in the chosen specialty. Assessment: Candidates are eligible to sit for the Part I Fellowship Examination after completing this phase.
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
Liquid chromatography–mass spectrometry is commonly used. It provides molecular mass and purity information. Other methods may include HPLC with ultraviolet detection.